What is the share price of Gujarat Themis Biosyn Ltd (GUJTHEM) today?
The share price of GUJTHEM as on 17th July 2025 is ₹371.25. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Gujarat Themis Biosyn Ltd (GUJTHEM) share?
The past returns of Gujarat Themis Biosyn Ltd (GUJTHEM) share are- Past 1 week: 6.25%
- Past 1 month: 7.00%
- Past 3 months: 17.50%
- Past 6 months: 9.35%
- Past 1 year: 16.04%
- Past 3 years: 549.64%
- Past 5 years: 1396.17%
What are the peers or stocks similar to Gujarat Themis Biosyn Ltd (GUJTHEM)?
The peers or stocks similar to Gujarat Themis Biosyn Ltd (GUJTHEM) include:What is the dividend yield % of Gujarat Themis Biosyn Ltd (GUJTHEM) share?
The current dividend yield of Gujarat Themis Biosyn Ltd (GUJTHEM) is 0.27.What is the market cap of Gujarat Themis Biosyn Ltd (GUJTHEM) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Gujarat Themis Biosyn Ltd (GUJTHEM) is ₹2663.11 Cr as of 17th July 2025.What is the 52 week high and low of Gujarat Themis Biosyn Ltd (GUJTHEM) share?
The 52-week high of Gujarat Themis Biosyn Ltd (GUJTHEM) is ₹390 and the 52-week low is ₹192.35.What is the PE and PB ratio of Gujarat Themis Biosyn Ltd (GUJTHEM) stock?
The P/E (price-to-earnings) ratio of Gujarat Themis Biosyn Ltd (GUJTHEM) is 54.61. The P/B (price-to-book) ratio is 13.22.Which sector does Gujarat Themis Biosyn Ltd (GUJTHEM) belong to?
Gujarat Themis Biosyn Ltd (GUJTHEM) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Gujarat Themis Biosyn Ltd (GUJTHEM) shares?
You can directly buy Gujarat Themis Biosyn Ltd (GUJTHEM) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Gujarat Themis Biosyn Ltd
GUJTHEM Share Price
371.250.07% (-0.25)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
GUJTHEM Stock Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
GUJTHEM Performance & Key Metrics
GUJTHEM Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 54.62 | 13.22 | 0.27% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 37.39 | 6.48 | 0.78% |
GUJTHEM Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
GUJTHEM Company Profile
The company makes bulk drugs. It's R&D division focuses on developing fermentation cultures. The Company's products include Rifamycin-S, which is an intermediate for Rifampicin for the treatment of tuberculosis (TB), and Lovastatin.
SUNPHARMA
PE Ratio
37.34
37.34
1Y Return
6.85%
6.85%
Buy Reco %
84.85
84.85
CIPLA
PE Ratio
22.61
22.61
1Y Return
1.61%
1.61%
Buy Reco %
68.75
68.75
TORNTPHARM
PE Ratio
61.26
61.26
1Y Return
14.59%
14.59%
Buy Reco %
70.83
70.83
MANKIND
PE Ratio
54.42
54.42
1Y Return
23.40%
23.40%
Buy Reco %
81.25
81.25
DRREDDY
PE Ratio
18.53
18.53
1Y Return
5.28%
5.28%
Buy Reco %
48.39
48.39
GUJTHEM Forecast
GUJTHEM Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
GUJTHEM
GUJTHEM
Income
Balance Sheet
Cash Flow
Annual Normal View
GUJTHEM Income Statement
GUJTHEM Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 36.05 | 38.97 | 43.26 | 86.82 | 93.83 | 118.90 | 154.98 | 174.20 | 153.23 | 153.23 | ||||||||||
Raw Materials | 1.49 | 2.15 | 1.30 | 15.44 | 15.75 | 21.75 | 29.73 | 25.67 | 81.96 | 81.96 | ||||||||||
| Power & Fuel Cost | 17.99 | 19.33 | 20.20 | 22.86 | 16.57 | 21.73 | 26.41 | 26.53 | ||||||||||||
| Employee Cost | 4.42 | 4.46 | 5.17 | 6.43 | 7.11 | 7.08 | 7.75 | 10.21 | ||||||||||||
| Selling & Administrative Expenses | 0.85 | 1.10 | 1.39 | 1.64 | 1.86 | 2.31 | 6.66 | 8.51 | ||||||||||||
| Operating & Other expenses | 4.90 | 5.52 | 5.62 | 6.91 | 8.94 | 3.94 | 4.20 | 20.18 | ||||||||||||
EBITDA | 6.40 | 6.41 | 9.58 | 33.54 | 43.60 | 62.09 | 80.23 | 83.10 | 71.27 | 71.27 | ||||||||||
| Depreciation/Amortization | 1.12 | 1.15 | 1.22 | 1.36 | 1.73 | 2.23 | 2.58 | 3.54 | 5.37 | 5.38 | ||||||||||
| PBIT | 5.28 | 5.26 | 8.36 | 32.18 | 41.87 | 59.86 | 77.65 | 79.56 | 65.90 | 65.89 | ||||||||||
| Interest & Other Items | 0.41 | 0.42 | 0.16 | 0.92 | 0.98 | 0.83 | 0.18 | 0.23 | 0.36 | 0.36 | ||||||||||
| PBT | 4.87 | 4.84 | 8.20 | 31.26 | 40.89 | 59.03 | 77.47 | 79.33 | 65.54 | 65.53 | ||||||||||
| Taxes & Other Items | 0.50 | 0.97 | 1.79 | 7.59 | 10.71 | 15.41 | 19.50 | 20.18 | 16.77 | 16.77 | ||||||||||
| Net Income | 4.37 | 3.87 | 6.41 | 23.67 | 30.18 | 43.62 | 57.97 | 59.15 | 48.77 | 48.76 | ||||||||||
| EPS | 0.40 | 0.36 | 0.59 | 2.17 | 2.77 | 4.00 | 5.32 | 5.43 | 4.48 | 4.47 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.22 | 0.00 | 1.47 | 0.72 | 3.33 | 0.67 | 0.17 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.10 | 0.00 | 0.37 | 0.14 | 0.61 | 0.15 | 0.04 |
GUJTHEM Company Updates
FY 2025FY 2025
Investor Presentation
May 20PDF
GUJTHEM Stock Peers
GUJTHEM Past Performance & Peer Comparison
GUJTHEM Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation-basic on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation-basic on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Gujarat Themis Biosyn Ltd | 54.61 | 13.22 | 0.27% |
| Sun Pharmaceutical Industries Ltd | 37.34 | 5.63 | 0.94% |
| Cipla Ltd | 22.61 | 3.81 | 1.08% |
| Torrent Pharmaceuticals Ltd | 61.26 | 15.42 | 0.92% |
GUJTHEM Stock Price Comparison
Compare GUJTHEM with any stock or ETFCompare GUJTHEM with any stock or ETF
GUJTHEM
GUJTHEM Holdings
GUJTHEM Shareholdings
GUJTHEM Promoter Holdings Trend
GUJTHEM Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
GUJTHEM Institutional Holdings Trend
GUJTHEM Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
GUJTHEM Shareholding Pattern
GUJTHEM Shareholding Pattern
GUJTHEM Shareholding History
GUJTHEM Shareholding History
Foreign Institutions
Mutual Funds Invested in GUJTHEM
Mutual Funds Invested in GUJTHEM
No mutual funds holding trends are available
Top 3 Mutual Funds holding Gujarat Themis Biosyn Ltd
| Funds (Top 3) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 1.3019% | Percentage of the fund’s portfolio invested in the stock 3.99% | Change in the portfolio weight of the stock over the last 3 months 0.59% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 10/46 (+1) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.3372% | Percentage of the fund’s portfolio invested in the stock 0.49% | Change in the portfolio weight of the stock over the last 3 months 0.06% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 39/54 (-11) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.0006% | Percentage of the fund’s portfolio invested in the stock 0.08% | Change in the portfolio weight of the stock over the last 3 months 0.01% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 83/109 (-1) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing GUJTHEM stock
smallcases containing GUJTHEM stock
Looks like this stock is not in any smallcase yet.
GUJTHEM Events
GUJTHEM Events
GUJTHEM Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
GUJTHEM Dividend Trend
No dividend trend available
GUJTHEM Upcoming Dividends
GUJTHEM Upcoming Dividends
No upcoming dividends are available
GUJTHEM Past Dividends
GUJTHEM Past Dividends
Cash Dividend
Ex DateEx DateJul 15, 2024
Final
Final | Div/Share: ₹0.25
Dividend/Share
₹0.25
Ex DateEx Date
Jul 15, 2024
Cash Dividend
Ex DateEx DateFeb 22, 2024
Interim
Interim | Div/Share: ₹0.75
Dividend/Share
₹0.75
Ex DateEx Date
Feb 22, 2024
Cash Dividend
Ex DateEx DateSep 1, 2023
Final
Final | Div/Share: ₹1.00
Dividend/Share
₹1.00
Ex DateEx Date
Sep 1, 2023
Cash Dividend
Ex DateEx DateDec 1, 2022
Interim
Interim | Div/Share: ₹4.40
Dividend/Share
₹4.40
Ex DateEx Date
Dec 1, 2022
Cash Dividend
Ex DateEx DateAug 29, 2022
Final
Final | Div/Share: ₹4.00
Dividend/Share
₹4.00
Ex DateEx Date
Aug 29, 2022
GUJTHEM Stock News & Opinions
GUJTHEM Stock News & Opinions
Articles & Videos
Corporate
Board of Gujarat Themis Biosyn recommends final dividend
Gujarat Themis Biosyn announced that the Board of Directors of the Company at its meeting held on 20 May 2025, inter alia, have recommended the final dividend of Rs 0.67 per equity Share (i.e. 67%) , subject to the approval of the shareholders.Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Gujarat Themis Biosyn standalone net profit declines 24.48% in the March 2025 quarter
Net profit of Gujarat Themis Biosyn declined 24.48% to Rs 12.00 crore in the quarter ended March 2025 as against Rs 15.89 crore during the previous quarter ended March 2024. Sales declined 10.16% to Rs 37.74 crore in the quarter ended March 2025 as against Rs 42.01 crore during the previous quarter ended March 2024. For the full year,net profit declined 17.56% to Rs 48.77 crore in the year ended March 2025 as against Rs 59.16 crore during the previous year ended March 2024. Sales declined 11.20% to Rs 150.80 crore in the year ended March 2025 as against Rs 169.82 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales37.7442.01 -10 150.80169.82 -11 OPM %42.5049.82 -45.6546.37 - PBDT17.3221.88 -21 70.9182.88 -14 PBT16.0920.96 -23 65.5479.34 -17 NP12.0015.89 -24 48.7759.16 -18 Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Gujarat Themis Biosyn to announce Quarterly Result
Gujarat Themis Biosyn will hold a meeting of the Board of Directors of the Company on 20 May 2025.Powered by Capital Market - Live
2 months agoCapital Market - Live
Earnings
Gujarat Themis Biosyn standalone net profit declines 0.31% in the December 2024 quarter
Net profit of Gujarat Themis Biosyn declined 0.31% to Rs 12.97 crore in the quarter ended December 2024 as against Rs 13.01 crore during the previous quarter ended December 2023. Sales rose 1.91% to Rs 39.52 crore in the quarter ended December 2024 as against Rs 38.78 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales39.5238.78 2 OPM %47.7245.56 - PBDT18.9618.67 2 PBT17.4017.69 -2 NP12.9713.01 0 Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Gujarat Themis Biosyn to convene board meeting
Gujarat Themis Biosyn will hold a meeting of the Board of Directors of the Company on 14 February 2025.Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Board approved merger of Gujarat Themis Biosyn with Themis Medicare
The Board of Directors of Gujarat Themis Biosyn (GTBL) and Themis Medicare (TML) have approved a Scheme of Amalgamation of Gujarat Themis Biosyn with Themis Medicare. The Scheme is subject to approval of the secured creditors and shareholders of TML and GTBL, the stock exchanges, SEBI, NCLT and other regulatory approvals as may be required. This amalgamation will result in consolidation of businesses and integration of the entire product value chain under a single amalgamated entity, leading to significant synergies. Under the scheme, TML will issue and allot 118 equity shares of the face value of Re. 1 each, credited as fully paid-up, for every 100 equity shares of the face value of Re. 1 each fully paid-up, held by shareholders in GTBL.Powered by Capital Market - Live
7 months agoCapital Market - Live
Earnings
Gujarat Themis Biosyn standalone net profit declines 15.71% in the September 2024 quarter
Net profit of Gujarat Themis Biosyn declined 15.71% to Rs 10.57 crore in the quarter ended September 2024 as against Rs 12.54 crore during the previous quarter ended September 2023. Sales declined 12.19% to Rs 34.72 crore in the quarter ended September 2024 as against Rs 39.54 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales34.7239.54 -12 OPM %44.3542.26 - PBDT15.6417.76 -12 PBT14.2016.88 -16 NP10.5712.54 -16 Powered by Capital Market - Live
8 months agoCapital Market - Live
Corporate
Gujarat Themis Biosyn schedules board meeting
Gujarat Themis Biosyn will hold a meeting of the Board of Directors of the Company on 25 October 2024.Powered by Capital Market - Live
8 months agoCapital Market - Live
Spotlight
Gujarat Themis' Q1 PAT falls over 25% YoY to Rs 13 crore
This decline was primarily driven by a 21.7% YoY drop in net sales to Rs 38.83 crore. Total operating expenses also decreased by 22.2% to Rs 20.28 crore in the June'24 quarter. Consequently, PBIDT decreased by 22.4% YoY to Rs 19.07 crore in Q1 FY25, with a margin of 49.11% (down from 49.57% in Q1 FY24). Further, the company's depreciation charges increased by 53.3% YoY to Rs 1.15 crore during the period under review. As a result, profit before tax fell by 25% to Rs 17.86 crore in Q1 FY25 compared to Rs 23.81 crore in the corresponding quarter of the previous year. Gujarat Themis Biosyn is engaged in the manufacturing of APIs, namely, Rifamycin S and Rifamycin O. The scrip had declined 3.91% to end at Rs 483.75 on the BSE on Friday. In the last one year, the stock of Gujarat Themis Biosyn has surged 207.26% while the benchmark Sensex had risen 21.92% in the same period. Powered by Capital Market - Live
11 months agoCapital Market - Live
Corporate
Board of Gujarat Themis Biosyn appoints director
The Board of Gujarat Themis Biosyn has approved the appointment of K. G. Ananthakrishnan (DIN: 00019325) as an Additional Independent Director of the Company w.e.f. 26 July 2024. Powered by Capital Market - Live
11 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 12.03%, vs industry avg of 10.15%
Over the last 5 years, market share increased from 0.03% to 0.04%
Over the last 5 years, net income has grown at a yearly rate of 15.56%, vs industry avg of 20.04%